tiprankstipranks
Advertisement
Advertisement

DE:5Y6 Stock Latest News

Strong Efficacy, Favorable Safety, and Limited Competition Drive Buy Rating on COMPASS Pathways’ COMP360
RatingsStrong Efficacy, Favorable Safety, and Limited Competition Drive Buy Rating on COMPASS Pathways’ COMP360
11d ago
CMPS
Compass Pathways: Strengthened Balance Sheet, Advancing COMP360 Through Pivotal Milestones Supports Buy Rating
PremiumRatings
Compass Pathways: Strengthened Balance Sheet, Advancing COMP360 Through Pivotal Milestones Supports Buy Rating
14d ago
CMPS
Psychedelic: Compass Pathways, NRx Pharma report earnings results
PremiumThe Fly
Psychedelic: Compass Pathways, NRx Pharma report earnings results
15d ago
ATAI
CMPS
Compass Pathways price target lowered to $18 from $20 at Canaccord
PremiumThe Fly
Compass Pathways price target lowered to $18 from $20 at Canaccord
16d ago
CMPS
Compass Pathways price target raised to $14 from $11 at Stifel
PremiumThe Fly
Compass Pathways price target raised to $14 from $11 at Stifel
16d ago
CMPS
Compass Pathways price target lowered to $16 from $18 at Morgan Stanley
PremiumThe FlyCompass Pathways price target lowered to $16 from $18 at Morgan Stanley
16d ago
CMPS
Compass Pathways reports Q4 EPS ($1.00) vs. (63c) last year
Premium
The Fly
Compass Pathways reports Q4 EPS ($1.00) vs. (63c) last year
17d ago
CMPS
Compass Pathways sees cash runway into 2028
Premium
The Fly
Compass Pathways sees cash runway into 2028
17d ago
CMPS
Neuronetics price target lowered to $3 from $7 at Canaccord
PremiumThe Fly
Neuronetics price target lowered to $3 from $7 at Canaccord
23d ago
CMPS
STIM
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
PremiumRatings
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
26d ago
CMPS
Psychedelic: Exclusive talk with nonprofit organization MAPS
PremiumThe Fly
Psychedelic: Exclusive talk with nonprofit organization MAPS
2M ago
ATAI
CMND
COMPASS Pathways Announces $150 Million Public Offering
PremiumCompany Announcements
COMPASS Pathways Announces $150 Million Public Offering
2M ago
8K
CMPS
Compass Pathways 17.5M share Secondary priced at $8.00
PremiumThe FlyCompass Pathways 17.5M share Secondary priced at $8.00
2M ago
CMPS
Compass Pathways price target raised to $22 from $21 at RBC Capital
Premium
The Fly
Compass Pathways price target raised to $22 from $21 at RBC Capital
2M ago
CMPS
Compass Pathways price target raised to $18 from $11 at Morgan Stanley
Premium
The Fly
Compass Pathways price target raised to $18 from $11 at Morgan Stanley
2M ago
CMPS
Compass Pathways price target raised to $20 from $15 at Canaccord
PremiumThe Fly
Compass Pathways price target raised to $20 from $15 at Canaccord
2M ago
CMPS
Compass Pathways announces $150M American Depositary Shares offering
PremiumThe Fly
Compass Pathways announces $150M American Depositary Shares offering
2M ago
CMPS
Midday Fly By: Warner Bros. reopens Paramount talks
PremiumThe Fly
Midday Fly By: Warner Bros. reopens Paramount talks
2M ago
DG
DHR
Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS
PremiumRatings
Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS
2M ago
CMPS
COMPASS Pathways Reports Positive Phase 3 Results in TRD
PremiumCompany AnnouncementsCOMPASS Pathways Reports Positive Phase 3 Results in TRD
2M ago
8K
CMPS
Compass Pathways achieves primary endpoint in Phase 3 COMP006 trial
Premium
The Fly
Compass Pathways achieves primary endpoint in Phase 3 COMP006 trial
2M ago
CMPS
Psychedelic: Clearmind reports additional CMND-100 safety results
Premium
The Fly
Psychedelic: Clearmind reports additional CMND-100 safety results
2M ago
PBM
AVTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >